Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.

Retrospective data analysis showed concordance between laboratory measured and iDose-predicted IFX level in 70% of patients. iDose-assisted management achieved clinical remission and cost reduction.